Condition: Advanced Solid Tumor · Metastatic Solid Tumor · Sponsor: Artios Pharma Ltd
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.
This description comes directly from the study's public registry record.
Artios Pharma · +44 (0)1223 867 900 · info@artios.com
Always discuss trial participation with your own doctor first.
| South Texas Accelerated Research Therapeutics (START) - Midwest | Grand Rapids, Michigan, United States | Active Not Recruiting |
| Memorial Sloan-Kettering Cancer Center (MSKCC) | New York, New York, United States | Active Not Recruiting |
| Stephenson Cancer Center - Oncology | Oklahoma City, Oklahoma, United States | Active Not Recruiting |
| Jefferson University Hospitals - Kimmel Cancer Center | Philadelphia, Pennsylvania, United States | Active Not Recruiting |
| SCRI oncology partners | Nashville, Tennessee, United States | Completed |
| Mary Crowley Cancer Center - Clinic | Dallas, Texas, United States | Completed |
| The University of Texas - MD Anderson Cancer Center | Houston, Texas, United States | Active Not Recruiting |
| Hospital Universitario Clínico San Cecilio | Granada, Andalusia, Spain | Recruiting |
| Hospital Clínico Universitario de Valladolid | Valladolid, Castille and León, Spain | Recruiting |
| Hospital de la Santa Creu i Sant Pau | Barcelona, Catalonia, Spain | Recruiting |
| Hospital San Pedro de Alcántara | Cáceres, Extremadura, Spain | Recruiting |
| Hospital Universitario 12 de Octubre | Madrid, Madrid, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05898399